|
MEGLUMINE (Methylglucamine)
|
|
15
|
1838
|
March 12, 2024
|
|
LOQ for small nitrosamines
|
|
1
|
230
|
March 11, 2024
|
|
AI limit for N-Nitroso Losartan
|
|
4
|
329
|
March 9, 2024
|
|
Define MDD to calculate limit
|
|
39
|
11522
|
March 6, 2024
|
|
Ribociclib Succinate NDSRIs limit clarification related
|
|
6
|
568
|
March 5, 2024
|
|
AI value for Nitroso Folic acid
|
|
4
|
1421
|
February 26, 2024
|
|
AI for en Indole struktur (N-Nitroso melatonin)
|
|
8
|
1173
|
February 20, 2024
|
|
Risk characterization of N-nitrosodimethylamine in pharmaceuticals -Pub
|
|
6
|
559
|
February 16, 2024
|
|
Developing and validating read-across workflows that enable decision making for toxicity and potency: Case studies with N-nitrosamines -Pub
|
|
4
|
380
|
February 14, 2024
|
|
Nitrosamines Severity (impact) - a quantitative model proposal?
|
|
3
|
760
|
February 12, 2024
|
|
Defining nitrosamine acceptable intake based on technical feasibible limit rather than CPCA
|
|
6
|
310
|
February 11, 2024
|
|
N- nitroso Nitazoxanide
|
|
1
|
266
|
February 8, 2024
|
|
TGA (Australia) :australia: Updates Published Acceptable Intakes
|
|
3
|
562
|
February 7, 2024
|
|
Aromatic nitrogen "Is it possible for aromatic nitrogen to convert nitrosamine?"- Indole
|
|
10
|
1457
|
February 2, 2024
|
|
Nitrosamine Impurities in Topical Drug Product
|
|
3
|
489
|
February 3, 2024
|
|
N-nitroso Vonoprazan AI 96 ng/day- FDA
|
|
5
|
2143
|
January 29, 2024
|
|
Limit for NDSRI
|
|
3
|
935
|
January 29, 2024
|
|
Updated EMA-Acceptable intakes (AIs) established for N-nitrosamines
|
|
20
|
3133
|
January 29, 2024
|
|
How to identify NDSRI for an API
|
|
5
|
536
|
January 24, 2024
|
|
The comprehensive prediction of carcinogenic potency and tumorigenic dose (TD50) for two problematic N-nitrosamines in food: NMAMPA and NMAMBA using toxicology in silico methods -Pub
|
|
0
|
191
|
January 23, 2024
|
|
A quick (dumb) question
|
|
10
|
830
|
January 22, 2024
|
|
N-nitroso-Impurity C in Metamizol Drug product
|
|
11
|
1126
|
January 22, 2024
|
|
Confidence score calculation for the carcinogenic potency categorization approach (CPCA) predictions for N-nitrosamines
|
|
5
|
1030
|
January 11, 2024
|
|
Nitroso-melatonin
|
|
3
|
544
|
January 4, 2024
|
|
Calculation of allowable limit in drug product with two API's
|
|
3
|
578
|
January 4, 2024
|
|
AI limit for N-nitroso betahistine?
|
|
26
|
2944
|
January 4, 2024
|
|
NDSRI in metronidazole
|
|
1
|
589
|
December 28, 2023
|
|
What should be the AI for N-Nitrosamines where CPCA doesn't apply (e.g. N-Nitroso Pyrrole Analogues where alpha carbon directly double bonded to hetero atom)?
|
|
1
|
662
|
December 27, 2023
|
|
Calculation of Nitrosamines AI not covered by CPCA
|
|
3
|
652
|
December 20, 2023
|
|
Australia TGA - postpone until end of Jun 2024 NTTP 37ng/day
|
|
0
|
329
|
December 15, 2023
|